Page 5 - Interim Analysis News Today

Researchers identified risk factors for and the prevalence of persistent pulmonary tissue alterations among hospitalized coronavirus disease 2019 (COVID-19) patients.

In a new study published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine, researchers sought to determine the percentage of COVID-19 patients discharged from the hospital who had a type of fibrotic lung damage, known as interstitial lung disease, that requires ongoing follow-up care.

Interstitial lung disease is known to cause severe lung damage

Get latest articles and stories on Health at LatestLY. COVID-19 often leads to a number of health issues as side-effects even after one recovers from it. According to a study by American Thoracic Society, a number of COVID-19 patients suffer from lung disease after being discharged from hospitals. Health News | Hospitalization During COVID-19 Damages Lungs: Study.

21 scientific presentations, including 7 late breakers, showcase the breadth of UCBs portfolio, reinforcing commitment to improving the lives of people living...

Presentation to highlight data from the ongoing long-term open-label extension study of leniolisib, a PI3Kδ inhibitor under investigation for APDS...

Interim Analysis for KALAHARI trial planned by Year-End 2022 with Full Top-Line Data Expected in Second half of 2023 Leuven, BELGIUM, Boston, MA, US - November 18, 2022 - 10:00

Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results...

Could oral taxane chemotherapies outperform traditional options? Here, Colin Freund, Modra Pharmaceuticals CEO explores their benefits.

Interim data from phase III HAVEN 7 study reinforce Hemlibra's efficacy and safety in infants with severe haemophilia A without factor VIII inhibitors1New and updated data support use of Polivy in diffuse